NLS Pharmaceutics AG Market Cap ($3.97 Million)
Market Cap & Net Worth: NLS Pharmaceutics AG (NLSP)
NLS Pharmaceutics AG market cap. NLS Pharmaceutics AG (NASDAQ:NLSP) has a market capitalization of $3.97 Million ($3.97 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28973 globally and #5942 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NLS Pharmaceutics AG's stock price $0.76 by its total outstanding shares 5206629 (5.21 Million). Also see NLSP cash generation efficiency for how efficiently the company converts equity into cash flow.
NLS Pharmaceutics AG Market Cap History (2021–2025)
NLS Pharmaceutics AG market cap history from 2021 to 2025. Data shows change from $231.17 Million to $3.97 Million (-65.23% CAGR). Check NLS Pharmaceutics AG share price for real-time trading data and today's change.
Index Memberships
NLS Pharmaceutics AG is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #837 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2669 of 3165 |
Weight: NLS Pharmaceutics AG's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NLS Pharmaceutics AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NLS Pharmaceutics AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is NLS Pharmaceutics AG growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NLSP by Market Capitalization
Companies near NLS Pharmaceutics AG in the global market cap rankings as of November 4, 2026. Also see NLSP total assets for a full breakdown of the balance sheet.
Key companies related to NLS Pharmaceutics AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of NLS Pharmaceutics AG (2021–2025)
Market capitalization of NLS Pharmaceutics AG from 2021 to today. Between 2021 and today, NLS Pharmaceutics AG's market cap moved from $231.17 Million to $ 3.97 Million, with a yearly change of -65.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.97 Million | -63.89% |
| 2024 | $10.99 Million | -91.06% |
| 2023 | $122.86 Million | -54.27% |
| 2022 | $268.66 Million | +16.22% |
| 2021 | $231.17 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 29th, 2026 the market cap of NLS Pharmaceutics AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.97 Million USD |
| MoneyControl | $3.97 Million USD |
| MarketWatch | $3.97 Million USD |
| marketcap.company | $3.97 Million USD |
| Reuters | $3.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more